drugset / Trial / NCT00246220

A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.

NCT00246220

Phase 3 Completed 402 enrolled Janssen Pharmaceutica N.V., Belgium
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of three doses of prolonged-release methylphenidate (a central nervous system (CNS) stimulant) in adult patients with attention deficit/hyperactivity disorder (ADHD).

Timeline

Start
2005-03
Primary completion
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 18 mg Oral
Subject Methylphenidate Small molecule 36 mg Oral
Subject Methylphenidate Small molecule 72 mg Oral